Jane Chang

415 total citations
50 papers, 218 citations indexed

About

Jane Chang is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Chang has authored 50 papers receiving a total of 218 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Surgery, 18 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Chang's work include Bladder and Urothelial Cancer Treatments (24 papers), Economic and Financial Impacts of Cancer (11 papers) and Urinary and Genital Oncology Studies (11 papers). Jane Chang is often cited by papers focused on Bladder and Urothelial Cancer Treatments (24 papers), Economic and Financial Impacts of Cancer (11 papers) and Urinary and Genital Oncology Studies (11 papers). Jane Chang collaborates with scholars based in United States, United Kingdom and Germany. Jane Chang's co-authors include Vivek Pawar, Petros Grivas, Kathleen M. Aguilar, Christopher Ngai, Bhakti Arondekar, Xinke Zhang, Jie Zhou, Eric Nadler, Mark P. Connolly and Paul Cislo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Jane Chang

46 papers receiving 214 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane Chang United States	9	103	92	75	26	23	50	218
Olga Kozyreva United States	10	146 1.4×	98 1.1×	96 1.3×	29 1.1×	47 2.0×	46	244
Dennis L. Sacdalan Philippines	6	236 2.3×	44 0.5×	77 1.0×	18 0.7×	19 0.8×	16	290
Leila Bengrine France	9	168 1.6×	90 1.0×	71 0.9×	21 0.8×	23 1.0×	24	232
Pierre-Emmanuel Brachet France	6	47 0.5×	32 0.3×	39 0.5×	12 0.5×	10 0.4×	18	118
B. Lefébure France	10	159 1.5×	214 2.3×	61 0.8×	41 1.6×	10 0.4×	25	345
Regina Gironés Sarrió Spain	6	81 0.8×	54 0.6×	73 1.0×	17 0.7×	6 0.3×	28	161
Aamir Ali Syed Pakistan	9	134 1.3×	148 1.6×	66 0.9×	45 1.7×	7 0.3×	55	278
Xin Song China	9	54 0.5×	40 0.4×	42 0.6×	21 0.8×	22 1.0×	28	226
Debora Canuti Italy	10	145 1.4×	82 0.9×	177 2.4×	46 1.8×	55 2.4×	20	352
Л. В. Болотина Russia	6	67 0.7×	125 1.4×	74 1.0×	13 0.5×	22 1.0×	87	219

Countries citing papers authored by Jane Chang

Since Specialization

Citations

This map shows the geographic impact of Jane Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Chang more than expected).

Fields of papers citing papers by Jane Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Chang. The network helps show where Jane Chang may publish in the future.

Co-authorship network of co-authors of Jane Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Chang. A scholar is included among the top collaborators of Jane Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Chang. Jane Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fay, André P., Karim Fizazi, Nobuaki Matsubara, et al.. (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet Oncology. 26(4). 481–490. 1 indexed citations

Clark, O, Akira Yuasa, Shigeru Sugiyama, et al.. (2024). Treatment Patterns in Metastatic Bladder Cancer in Japan: Results of the CancerMPact ^® Survey 2020. Future Oncology. 20(10). 603–611. 1 indexed citations

Shore, Neal D., Michael S. Broder, Pedro C. Barata, et al.. (2024). Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy. European Urology Oncology. 8(1). 94–104. 1 indexed citations

Thompson, Allison, et al.. (2024). Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey. Urologic Oncology Seminars and Original Investigations. 42(3). 70.e1–70.e10. 1 indexed citations

Clark, O, et al.. (2024). Economic Impact of Bladder Cancer in the USA. PharmacoEconomics - Open. 8(6). 837–845. 4 indexed citations

Clark, O, et al.. (2023). Physician Reported Treatment Patterns and Outcomes in Metastatic Bladder Cancer in the USA: The CancerMPact ^® Survey 2020. Future Oncology. 20(10). 613–622. 2 indexed citations

Bullement, Ash, Simon J. Crabb, Robert J. Jones, et al.. (2023). Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology. 20(8). 459–470.

Su, Po‐Jung, Ying Xiao, E.Q. Wu, et al.. (2023). A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan. Cancer Reports. 6(10). e1887–e1887. 2 indexed citations

Fay, André P., Karim Fizazi, Nobuaki Matsubara, et al.. (2023). 1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study. Annals of Oncology. 34. S980–S981. 1 indexed citations

10.

Kearney, Mairead, et al.. (2023). Real-World Analysis of Treatment Patterns and Platinum-Based Treatment Eligibility of Patients With Metastatic Urothelial Cancer in 5 European Countries. Clinical Genitourinary Cancer. 22(1). e136–e147.e1. 8 indexed citations

11.

Xiao, Yunbei, Simon J. Crabb, Ash Bullement, et al.. (2022). POSC4 Modeling Health-Related Outcomes With Avelumab as a First-Line Maintenance Treatment Following Chemotherapy vs. Best Supportive Care (BSC) for Patients With Locally Advanced or Metastatic Urothelial Cancer in the UK. Value in Health. 25(1). S32–S33. 1 indexed citations

12.

Jääskeläinen, SK, et al.. (2022). POSC66 Cost-Effectiveness of Avelumab as First-Line Maintenance Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Finland. Value in Health. 25(1). S99–S99. 1 indexed citations

13.

Kapetanakis, Venediktos, et al.. (2021). PCN217 Health State Utility Values of Patients With Locally Advanced or Metastatic Urothelial Carcinoma: Analysis Based on the JAVELIN Bladder 100 Trial. Value in Health. 24. S60–S60.

14.

Peipert, John Devin, Jane Chang, Alessandra di Pietro, et al.. (2021). PCN214 Responsiveness and Responder Definitions for the NCCN/FACT Bladder Symptom Index (NFBISI-18) in Individuals With Locally Advanced or Metastatic Urothelial Cancer (UC). Value in Health. 24. S59–S60. 2 indexed citations

15.

Grivas, Petros, Caroline Huber, Vivek Pawar, et al.. (2021). Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies. Clinical Genitourinary Cancer. 20(2). 114–122. 5 indexed citations

16.

Powles, Thomas, Evgeny Kopyltsov, Francis Parnis, et al.. (2020). 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). Annals of Oncology. 31. S578–S579. 8 indexed citations

17.

Trigg, Andrew, Mark Kelly, Laura Iadeluca, et al.. (2019). PCN284 PSYCHOMETRIC EVALUATION AND SCORE INTERPRETATION OF THE NCCN-FACT OVARIAN SYMPTOM INDEX-18 IN PATIENTS WITH ADVANCED OVARIAN CANCER: REAL-WORLD EVIDENCE. Value in Health. 22. S110–S110. 1 indexed citations

18.

O’Byrne, Kenneth J., et al.. (2018). PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY. Value in Health. 21. S70–S71. 1 indexed citations

19.

Chang, Jane, et al.. (2017). Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clinical Drug Investigation. 37(6). 525–533. 3 indexed citations

20.

Seal, Brian, Kenneth M. Shermock, Carl V. Asche, et al.. (2015). Evaluating the Cost of Treating Bladder Cancer With and Without Metastases. Value in Health. 18(3). A201–A201. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact